Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...
Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer. This is an ASCO Meeting Abstract from the 2026 ...
The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway ...
Multiple molecular pathways play a role in gastric cancer development, influencing how genetic and environmental factors interact to drive tumor growth and progressiA recent study by researchers at ...
BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, ...
Laekna Inc. outlicensed select rights to LAE-002 (afuresertib), an oral pan-AKT kinase inhibitor licensed from Novartis AG in 2018, to Qilu Pharmaceutical Co. Ltd. under a potential ¥2.045 billion ...
MedPage Today on MSN
PAM inhibitor approved for HR-positive breast cancer
Gedatolisib is approved in combination with fulvestrant, with or without palbociclib ...
The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results